Target intelligence / Profile preview

Endoplasmic reticulum membrane-associated RNA degradation protein (ERMARD)

Target
ERMARD
Molecular classification
Other (Transmembrane protein localized to the endoplasmic reticulum membrane; not classified as receptor, enzyme, ion channel, transporter, or transcription factor)
01

Overview

Endoplasmic reticulum membrane-associated RNA degradation protein (ERMARD) is a transmembrane protein encoded by the ERMARD (C6orf70) gene, localizing to the endoplasmic reticulum and featuring two transmembrane domains near its C-terminus. It is implicated in the process of neuronal migration during brain development, as gene knockout models in rats show impacts on this process. Mutations in ERMARD are associated with periventricular nodular heterotopia type 6 (PVNH6), a developmental malformation of the cortex characterized by misplaced neurons. The protein is not classified as a receptor, enzyme, or transporter, and its precise molecular function remains not well characterized except for an implied role in RNA surveillance or degradation at the endoplasmic reticulum, based on its name and localization. There are no approved drugs or candidate molecules that target ERMARD, and it is not considered a therapeutic target or biomarker in current medical practice.

Other names
ERMARDC6orf70PVNH6dJ266L20.3FLJ11152Endoplasmic reticulum membrane-associated RNA degradation protein
02

Mechanism of action

None reported; mechanisms of action for drugs are not available since ERMARD is not a known therapeutic target

03

Biological functions

Neuronal migration (especially during embryonic development)RNA degradation or RNA surveillance at the endoplasmic reticulum (implied by name; direct functional studies are limited)
04

Disease associations

Periventricular nodular heterotopia type 6 (PVNH6), a neurodevelopmental disorder associated with defective neuronal migration
05

Safety considerations

None reported; not used therapeutically and no data on drug safety
06

Interacting drugs

None reported; no drugs shown to interact directly with ERMARD in current public datasets
07

Biomarkers

None; ERMARD/is not established as a biomarker for patient selection or response monitoring

Beyond the preview

Go deeper on Endoplasmic reticulum membrane-associated RNA degradation protein (ERMARD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endoplasmic reticulum membrane-associated RNA degradation protein (ERMARD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call